Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.

Journal of neuro-oncology - 2 Mar 2026

Yenidogan Irem, Tabori Uri, Das Anirban

Abstract excerpt

PURPOSE: Immune checkpoint inhibitors (ICI) have transformed cancer therapy but remain of limited efficacy in pediatric central nervous system tumors, which are characterized by low tumor mutational burden, sparse antigen presentation, and profoundly immunosuppressive microenvironments. CONTENT: Across pediatric trials, ICI monotherapy targeting the PD-1/PD-L1 axis has largely failed to show substantive benefits,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Blood-Brain Barrier

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Central Nervous System Neoplasms

Share to Drug Delivery Systems

Share to Gastrointestinal Microbiome

Share to Immune Checkpoint Inhibitors

Share to Neoadjuvant Therapy

Share to Tumor Microenvironment

Source

Identifiers

PMID: 41772324
DOI: 10.1007/s11060-026-05491-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.PMID 41772324Read ↗

Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.Semantic proximity Read ↗

Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System TumorsSemantic proximity Read ↗

Immuno-oncologic profiling of pediatric CNS tumors reveals major clinical significance of the tumor immune microenvironmentSemantic proximity Read ↗

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Semantic proximity Read ↗

Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment.Semantic proximity Read ↗

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiencySemantic proximity Read ↗

Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.Semantic proximity Read ↗

The Growing Relevance of Immunoregulation in Pediatric Brain TumorsSemantic proximity Read ↗

Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity.Semantic proximity Read ↗

Advances in the biology and treatment of pediatric central nervous system tumors.Semantic proximity Read ↗

Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targetsSemantic proximity Read ↗

Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.